Efficacy of Multi-disciplinary Integrated Post-acute Care in Patients Admission for Heart Failure

November 16, 2020 updated by: National Taiwan University Hospital
Background: Clinical heart failure patients always suffering from (1) worsen symptoms such as decreased activity tolerance, end-to-end breathing and excessive body fluid volume; (2) high medical expenses results from hospitalization; (3) reduced quality of life . In 2018, following instruction from National Health Insurance Administration (NHIA), the National Taiwan University Hospital (NTUH) undertook National Health Insurance post-acute care program, PAC in charge of heart failure patients by multi-disciplinary integrated to reduce acute exacerbations(AE), control symptoms, improve quality of life and increase survival rate.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Objective: To evaluate the outcome of patients with heart failure who been taken are of multi-disciplinary integrated instructed by National Health Insurance Administration (NHIA)

Methods: Use retrospective case contrl study. Adopted the hospitalized patients diagnosed with heart failure in the NTUH as the research sample, and collected the retrospective data for analysis in a two-group study design. (1) The experimental group is a patient who was managed by the NHIA 's acute post-care plan. Provide interdisciplinary comprehensive care in accordance with the norms and conduct health education during hospitalization. Hospitalized Chinese pharmacists, dietitians, physiotherapists and case managers participate in health education and will continue to be interviewed and have heart consultations within six months of discharge. (2)The control group received traditional health education in general care and routine health care.

Time of review: From February 2, 2018, the implementation of the National Health Insurance Agency's acute post-care plan day to December 31, 2019, and continuous tracking of effectiveness for one year.

Exclusion conditions: (1) Age over20 years, (2) long-term dialysis, (3) unconsciousness, (4) complete bed rest without self-care ability, (5) those with ventilator dependence, (6) ventricular assist device (VAD) has been implanted, (7) heart transplants , (8) refused to join the research.

The monitoring indicators: Hospitalization rate within 180 days, mortality rate within one year , functional recovery, left ventricle ejection fraction (LVEF), NT-pro BNP, etc.

Study Type

Observational

Enrollment (Actual)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
    • No. 7, Zhongshan S. Rd., Zhongzheng Dist., Tai
      • Taipei, No. 7, Zhongshan S. Rd., Zhongzheng Dist., Tai, Taiwan, 100225
        • NTUH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Exclusion Criteria:

  • (1) Age over20 years, (2) long-term dialysis, (3) unconsciousness, (4) complete bed rest without self-care ability, (5) those with ventilator dependence, (6) ventricular assist device (VAD) has been implanted, (7) heart transplants , (8) refused to join the research.

Description

Inclusion Criteria:

Clinical diagnosis of Heart Failure

  • The experimental group is a patient who was managed by the NHIA 's acute post-care plan. Provide interdisciplinary comprehensive care in accordance with the norms and conduct health education during hospitalization. Hospitalized Chinese pharmacists, dietitians, physiotherapists and case managers participate in health education and will continue to be interviewed and have heart consultations within six months of discharge.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Other

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
HF-PAC
(1) The experimental group is a patient who was managed by the NHIA 's acute post-care plan. Provide interdisciplinary comprehensive care in accordance with the norms and conduct health education during hospitalization. Hospitalized Chinese pharmacists, dietitians, physiotherapists and case managers participate in health education and will continue to be interviewed and have heart consultations within six months of discharge.
Other: Not intervention.Use retrospective case contrl study.
Use retrospective case contrl study.
Other Names:
  • Use retrospective case contrl study.
HF-non PAC
(2)The control group received traditional health education in general care and routine health care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hospitalization rate within 180 days
Time Frame: within 180 days
Hospitalization rate
within 180 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Taiwan University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2018

Primary Completion (Actual)

December 31, 2019

Study Completion (Actual)

November 16, 2020

Study Registration Dates

First Submitted

October 30, 2020

First Submitted That Met QC Criteria

November 16, 2020

First Posted (Actual)

November 20, 2020

Study Record Updates

Last Update Posted (Actual)

November 20, 2020

Last Update Submitted That Met QC Criteria

November 16, 2020

Last Verified

February 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 202006182RIND

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe